Noncompaction Cardiomyopathy Management
Treat noncompaction cardiomyopathy (NCCM) with standard guideline-directed heart failure therapy (ACE inhibitors/ARBs, beta-blockers, diuretics, aldosterone antagonists), anticoagulation for all patients regardless of CHA2DS2-VASc score, ICD for secondary prevention or primary prevention with LVEF ≤35%, and close monitoring for arrhythmias and thromboembolism.
Heart Failure Management
Apply standard heart failure with reduced ejection fraction (HFrEF) therapy to all NCCM patients with systolic dysfunction:
- ACE inhibitors or ARBs are recommended for all patients with reduced LVEF unless contraindicated 1
- Beta-blockers (bisoprolol, carvedilol, or sustained-release metoprolol succinate) for all stable patients with current or prior HF symptoms 1
- Aldosterone antagonists (spironolactone 12.5-25 mg daily) in patients with moderately severe symptoms who can be monitored for hyperkalemia (K+ <5.0 mEq/L) and renal function (creatinine ≤2.5 mg/dL in men, ≤2.0 mg/dL in women) 2
- Diuretics with salt restriction for fluid retention 1
The evidence base for NCCM treatment derives from general HF guidelines, as no NCCM-specific trials exist. However, recent case series suggest NCCM may show limited response to standard GDMT compared to other cardiomyopathies 3, warranting closer monitoring and earlier consideration of advanced therapies.
Anticoagulation Strategy
Anticoagulate all NCCM patients with atrial fibrillation regardless of CHA2DS2-VASc score 4. Use direct oral anticoagulants (DOACs) as first-line, with warfarin as second-line 4.
For patients in sinus rhythm with LVEF <35%, strongly consider anticoagulation due to the unique thrombogenic substrate created by deep intertrabecular recesses causing blood stasis 5, 6. The deep recesses predispose to thrombus formation independent of global systolic dysfunction or atrial fibrillation 5. While guidelines don't mandate anticoagulation in sinus rhythm, the thromboembolic risk in NCCM (occurring in 63-69% from cardiac sources) exceeds that of similar populations 5.
Anticoagulate patients with documented left ventricular thrombus 6. DOACs are increasingly used, though warfarin remains standard for documented thrombus 5.
Arrhythmia Management and Device Therapy
ICD Implantation
Secondary prevention (Class I): ICD is recommended for patients with history of cardiac arrest, ventricular fibrillation, or hemodynamically destabilizing ventricular tachycardia 1, 2
Primary prevention:
- ICD recommended (Class I) for LVEF ≤30% with NYHA class II-III symptoms on optimal medical therapy, with reasonable expectation of survival >1 year 2
- ICD reasonable (Class IIa) for LVEF 31-35% 7
- Do not implant in NYHA class IV patients not expected to improve and not transplant candidates 7
Arrhythmia Treatment
Avoid routine antiarrhythmic drugs except for symptomatic sustained ventricular tachycardia, where amiodarone is preferred 8, 9. Most antiarrhythmic drugs should be avoided as they can worsen HF 1.
For atrial fibrillation:
- Rate control with beta-blockers, digoxin, or combination 8
- If rhythm control needed, use amiodarone only 8
- Consider cardioversion for persistent AF depending on duration and left atrial size 8
Cardiac Resynchronization Therapy (CRT)
CRT with or without ICD is recommended for patients with:
- LVEF ≤35%
- Sinus rhythm
- QRS duration ≥120 ms (particularly ≥150 ms)
- NYHA class III or ambulatory class IV despite optimal medical therapy 2
Consider CRT evaluation 90 days post-diagnosis if QRS ≥150 ms and LVEF remains ≤35% 10.
Follow-Up and Monitoring
Establish multidisciplinary heart failure care with close follow-up, as organized specialist care improves symptoms, reduces hospitalizations, and may reduce mortality 8.
Monitor for:
- Worsening HF symptoms requiring diuretic adjustment
- New arrhythmias (consider event monitor or implantable loop recorder) 11
- Thromboembolic events
- Response to GDMT (note: NCCM may show limited improvement compared to other cardiomyopathies) 3
Serial imaging with echocardiography to assess:
- LVEF trajectory
- Development of thrombus
- Progression of trabeculations
Advanced Therapies
Refer for heart transplant evaluation if:
- NYHA class III-IV despite GDMT 12
- Life-threatening ventricular arrhythmias refractory to therapy 12
- Progressive deterioration despite optimal management 3
LVAD as bridge to transplant is reasonable in advanced HF patients who are transplant candidates 12, though NCCM patients have smaller LV cavities which may complicate LVAD support 4.
Genetic Testing and Family Screening
Perform genetic testing in all NCCM patients, as >40 genes have been identified 5, 13.
Screen first-degree relatives with history, physical examination, ECG, and echocardiography 13. If a pathogenic variant is identified, test relatives for that specific variant.
Common Pitfalls
- Underdiagnosis on echocardiography alone - consider cardiac MRI for definitive diagnosis using noncompacted-to-compacted ratio >2.3 at end-systole 11, 14
- Delaying anticoagulation - the deep recesses create thrombogenic substrate even without AF or severe LV dysfunction 5, 6
- Expecting robust GDMT response - NCCM may show minimal LVEF improvement despite optimal therapy, requiring earlier consideration of advanced interventions 3
- Missing concurrent anomalies - comprehensive imaging may reveal coexisting conditions like anomalous coronary arteries 14